




CME FOUNDATION OF INDIA



**CME TITLE: NOVEL THERAPY TO
TREAT CKD ANEMIA IN INDIA**

EVENT REPORT

About Workshop

The CME Foundation of India, organized an academic CME on “Novel Therapy to Treat CKD Anemia in India” on 30th October 2025 at ESIC Kamgar Hospital, Kandivali (E), Mumbai. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

This CME was attended by physicians and nephrologists from ESIC Hospital and surrounding centers. The session by Dr. Nikita Pawar, covered various aspects of CKD anemia management such as understanding the unmet need in CKD anemia, limitations of current therapies, desidustat as a novel therapy in CKD management, its mechanism, and clinical application.

Date: 30th October 2025

Venue: ESIC Kamgar Hospital, Kandivali (E), Mumbai

No. of participants: 33

Agenda

Date: 30th October 2025

Time: 1:00 p.m. to 2:00 p.m.

Topics	Speaker	Timings
Registration		1:00 p.m. – 1:10 p.m.
Welcome Note		1:10 p.m. – 1:15 p.m.
Novel Therapy to treat CKD Anemia in India	Dr. Nikita Pawar (MBBS, MD Medicine, DNB Nephrology)	1:15 p.m. – 1:55 p.m.
Vote of Thanks		1:55 p.m. – 2:00 p.m.

Summary of the Novel Therapy to Treat CKD Anemia in India

Understanding the Unmet Need in CKD Anemia

Dr. Nikita Pawar began by outlining the burden of CKD-associated anemia in India, emphasizing its impact on patient outcomes, quality of life, and healthcare costs. She discussed the multifactorial causes of anemia in CKD, including iron deficiency, inflammation, and erythropoietin deficiency, highlighting the need for novel solutions beyond traditional therapies.

Limitations of Current Therapies

The presentation reviewed existing erythropoiesis-stimulating agents (ESAs) and iron supplementation strategies, addressing their limitations related to efficacy, safety concerns, and accessibility in the Indian population. Dr. Nikita Pawar highlighted the clinical gaps that often lead to suboptimal hemoglobin control and patient non-compliance.

Mechanism and Promise of Desidustat

A major focus of the CME was the novel mechanism of Desidustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Pawar explained how Desidustat activates the body's natural pathway for erythropoietin production, improves iron metabolism, and reduces hepcidin levels—offering a potentially safer and more convenient oral alternative to traditional ESA therapy.

Clinical Evidence and Practical Application

Dr. Nikita Pawar reviewed key clinical trial data demonstrating Desidustat's efficacy in raising hemoglobin, maintaining stability over time, and showing favorable tolerability. The discussion also included real-world evidence supporting its use in both dialysis-dependent and non-dialysis CKD patients. She elaborated on practical aspects such as patient selection, dosing, and monitoring during therapy.

Integration into Clinical Practice

The session concluded with an interactive discussion on how Desidustat can be integrated into existing CKD anemia management protocols in India. Participants discussed patient eligibility, cost-effectiveness, and strategies to improve adherence to therapy.


At the end of the CME, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the CME.

Snapshots of Success

Registration Counter



Lecture on Novel Therapy to Treat CKD Anemia in India





Developed by:

CME FOUNDATION OF INDIA

Building "A" Sahney Business Centre, 27 Kiroli Road, Vidyavihar (W), Mumbai - 400086
Tel: +91 22 61798600 | Website: www.cmefi.co.in